Beyond Air Sells NeuroNOS Stake to UNIVO for Equity and Milestone Payments

Key Facts

In a move reflecting a strategic shift to monetize investments while retaining upside potential, Beyond Air has signed a definitive agreement to sell its stake in NeuroNOS to UNIVO Pharmaceutical Industries. Under the terms of the deal, Beyond Air will receive ordinary shares representing 19.99% of UNIVO's issued share capital upon closing. The transaction also features a milestone-based payment structure that could provide up to $32.5 million in cash based on development and commercial success.

This divestiture allows Beyond Air to capitalize on its NeuroNOS investment without immediate capital expenditure, maintaining exposure through its new equity position in UNIVO. According to reports, the deal involves the transfer of intellectual property rights for specific development programs. By restructuring its holding into an equity stake and potential cash milestones, Beyond Air aims to mitigate clinical development risks while securing a pathway for future liquidity and financial growth.

As of the reporting date on August 25, 2026, specific price levels for the involved instruments were unavailable in the market data, leaving qualitative catalysts as the primary focus for investors. Market participants are looking ahead to the formal closing of the transaction and any regulatory approvals. Additionally, broader sector sentiment may be influenced by the upcoming release of the FOMC Minutes on August 19, which remains a key event for growth-oriented industries like biotechnology.